SARS-CoV-2 Secondary Attack Rates in Vaccinated and Unvaccinated Household Contacts during Replacement of Delta with Omicron Variant, Spain.
COVID-19
Delta variant
Omicron variant
SARS
SARS-CoV-2
Spain
contact tracing
coronavirus
coronavirus disease
respiratory infections
secondary attack rate
severe acute respiratory syndrome coronavirus 2
vaccine effectiveness
viruses
zoonoses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
pubmed:
30
8
2022
medline:
24
9
2022
entrez:
29
8
2022
Statut:
ppublish
Résumé
We performed a prospective, cross-sectional study of household contacts of symptomatic index case-patients with SARS-CoV-2 infection during the shift from Delta- to Omicron-dominant variants in Spain. We included 466 household contacts from 227 index cases. The secondary attack rate was 58.2% (95% CI 49.1%-62.6%) during the Delta-dominant period and 80.9% (95% CI 75.0%-86.9%) during the Omicron-dominant period. During the Delta-dominant period, unvaccinated contacts had higher probability of infection than vaccinated contacts (odds ratio 5.42, 95% CI 1.6-18.6), but this effect disappeared at ≈20 weeks after vaccination. Contacts showed a higher relative risk of infection (9.16, 95% CI 3.4-25.0) in the Omicron-dominant than Delta-dominant period when vaccinated within the previous 20 weeks. Our data suggest vaccine evasion might be a cause of rapid spread of the Omicron variant. We recommend a focus on developing vaccines with long-lasting protection against severe disease, rather than only against infectivity.
Identifiants
pubmed: 36037811
doi: 10.3201/eid2810.220494
pmc: PMC9514368
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1999-2008Références
N Engl J Med. 2021 Aug 19;385(8):759-760
pubmed: 34161702
Nat Med. 2022 May;28(5):1063-1071
pubmed: 35189624
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166
pubmed: 34437519
Lancet. 2022 Mar 5;399(10328):924-944
pubmed: 35202601
Lancet Infect Dis. 2022 Feb;22(2):183-195
pubmed: 34756186
Emerg Infect Dis. 2022 Mar;28(3):591-598
pubmed: 35195514
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Euro Surveill. 2021 Sep;26(39):
pubmed: 34596016
J Health Econ. 2021 Dec;80:102530
pubmed: 34563830
Emerg Infect Dis. 2021 Dec;27(12):3009-3019
pubmed: 34695369
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
PLoS One. 2021 Jun 16;16(6):e0249499
pubmed: 34133415
N Engl J Med. 2021 Dec 9;385(24):e83
pubmed: 34614327
JAMA Intern Med. 2021 Oct 1;181(10):1343-1350
pubmed: 34424260
MMWR Morb Mortal Wkly Rep. 2022 Mar 04;71(9):341-346
pubmed: 35238860
Front Physiol. 2021 Jan 12;11:571416
pubmed: 33510644
J Infect Dis. 2022 Apr 1;225(7):1129-1140
pubmed: 34888688
Int J Environ Res Public Health. 2022 Jun 30;19(13):
pubmed: 35805724
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
JAMA Netw Open. 2022 Apr 1;5(4):e229317
pubmed: 35482308
Euro Surveill. 2020 May;25(21):
pubmed: 32489179
J Infect Dis. 2021 Jan 4;223(1):62-71
pubmed: 33175145
JAMA Netw Open. 2021 Aug 2;4(8):e2122240
pubmed: 34448865
Emerg Infect Dis. 2022 May;28(5):998-1001
pubmed: 35290176
Lancet Infect Dis. 2022 Sep;22(9):1313-1320
pubmed: 35658998
Lancet. 2022 Jan 8;399(10320):152-160
pubmed: 34741818
Lancet Infect Dis. 2022 Feb;22(2):e52-e58
pubmed: 34534512
J Infect. 2020 Sep;81(3):357-371
pubmed: 32615199
JAMA Netw Open. 2021 Mar 1;4(3):e211085
pubmed: 33688964
Open Forum Infect Dis. 2022 Feb 20;9(5):ofac066
pubmed: 35392460
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Emerg Microbes Infect. 2022 Dec;11(1):337-343
pubmed: 34935594
N Engl J Med. 2022 Jan 27;386(4):340-350
pubmed: 35021002
Euro Surveill. 2021 Apr;26(15):
pubmed: 33860747
Public Health. 2021 Jun;195:132-134
pubmed: 34111802
Prev Med. 2022 Jan;154:106890
pubmed: 34800471
J Korean Med Sci. 2022 Jan 03;37(1):e12
pubmed: 34981682